Researchers at the University of California, Irvine, have developed glycan-dependent T cell recruiters (GlyTRs), a novel class of immunotherapeutics that selectively target tumor-associated carbohydrate antigens on cancers while sparing normal tissue. This velcro-like carbohydrate-binding technology enables safe and effective treatment across multiple solid tumor types—including breast, colon, lung, ovarian, pancreatic, and prostate cancers—overcoming challenges of toxicity that have limited other high-affinity antibody and CAR T cell therapies. The findings, published in Cell, represent a promising advancement toward broadly applicable and safer cancer immunotherapies.